Key facts
- It has raised $3.8M; the latest was Seed Round ($3.8M) in Mar 2025.
- Notable investors include High-Tech Gründerfonds, Bayern Kapital, Elaia Partners, Incubateur HEC Paris, Lumo Labs — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Hema.to
- ·The full record, as it builds
Funding rounds
No funding rounds for Hema.to are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hema.to
Developer of a clinical support software designed to provide end-to-end decision support from raw flow files to a diagnostic report. The company helps to empower hematology labs to increase efficiency while maintaining quality and ensuring full regulatory compliance across every sample, enabling healthcare providers to have tools tailored to clinical flow.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2021
- Employees
- 19
- Website
- hema.to/
- Ownership
- Privately Held (backing)
Hema.to doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hema.to shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hema.to in its N-PORT filings yet. We sweep new filings monthly.